Phreesia (NYSE:PHR) Earns Overweight Rating from Stephens

Key Points

• Phreesia's stock received an "overweight" rating from Stephens, with a target price of $32.00, indicating a potential upside of 1.70% from its previous close.
• Other analysts have also shown optimism, with Truist Financial raising its price objective to $35.00 and stating a "buy" rating, while the consensus rating stands at "buy" with a target price of $32.54.
• Insider trading activity includes significant share sales, with Director Mark Douglas Smith selling 7,000 shares and Evan Roberts selling 3,400 shares, which highlights ongoing changes in insider ownership.

Stephens reiterated their overweight rating on shares of Phreesia (NYSE:PHR - Free Report) in a research report released on Wednesday morning,Benzinga reports. Stephens currently has a $32.00 price objective on the stock.

PHR has been the subject of a number of other reports. Mizuho started coverage on Phreesia in a research note on Wednesday, August 27th. They set an "outperform" rating and a $36.00 price target for the company. DA Davidson raised Phreesia to a "strong-buy" rating in a research note on Tuesday, July 22nd. KeyCorp raised their price target on Phreesia from $28.00 to $35.00 and gave the stock an "overweight" rating in a research note on Monday, July 14th. Truist Financial lifted their price target on shares of Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a research note on Thursday, May 29th. Finally, Citigroup reaffirmed a "buy" rating on shares of Phreesia in a research note on Wednesday, May 28th. Thirteen equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $33.31.

Phreesia Trading Down 10.0%

Shares of NYSE:PHR traded down $3.12 during trading on Wednesday, hitting $28.09. The company had a trading volume of 2,671,573 shares, compared to its average volume of 819,069. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -66.88 and a beta of 0.72. Phreesia has a one year low of $17.07 and a one year high of $32.76. The company has a fifty day simple moving average of $28.34 and a two-hundred day simple moving average of $26.53. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.95 and a quick ratio of 1.95.

Phreesia (NYSE:PHR - Get Free Report) last posted its quarterly earnings data on Thursday, September 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.08. The business had revenue of $117.26 million during the quarter, compared to analyst estimates of $116.39 million. Phreesia had a negative return on equity of 9.00% and a negative net margin of 5.35%.The company's revenue for the quarter was up 14.9% on a year-over-year basis. During the same period last year, the company earned ($0.03) EPS. Phreesia has set its FY 2026 guidance at EPS. As a group, equities analysts forecast that Phreesia will post -1.1 earnings per share for the current year.

Insider Activity

In other news, SVP David Linetsky sold 23,729 shares of the stock in a transaction that occurred on Friday, June 27th. The shares were sold at an average price of $28.50, for a total transaction of $676,276.50. Following the transaction, the senior vice president directly owned 193,510 shares in the company, valued at approximately $5,515,035. This trade represents a 10.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Lisa Egbuonu-Davis sold 2,802 shares of the stock in a transaction that occurred on Thursday, June 26th. The shares were sold at an average price of $27.67, for a total transaction of $77,531.34. Following the transaction, the director owned 22,037 shares in the company, valued at approximately $609,763.79. This represents a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 119,874 shares of company stock valued at $3,587,618. 5.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Phreesia by 108.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company's stock worth $67,606,000 after purchasing an additional 1,377,904 shares in the last quarter. Loomis Sayles & Co. L P acquired a new stake in Phreesia in the 2nd quarter worth approximately $34,162,000. American Century Companies Inc. boosted its stake in Phreesia by 3,741.9% in the 1st quarter. American Century Companies Inc. now owns 983,440 shares of the company's stock worth $25,137,000 after purchasing an additional 957,842 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its stake in Phreesia by 133.6% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 1,271,832 shares of the company's stock worth $31,999,000 after purchasing an additional 727,384 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in Phreesia in the 1st quarter worth approximately $14,206,000. Institutional investors own 92.10% of the company's stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.